Poxel SA is a clinical-stage biopharmaceutical company developing innovative treatments for chronic serious diseases driven by metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes, and rare disorders such as adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). Its lead product, TWYMEEG (Imeglimin), a first-in-class oral therapy targeting mitochondrial dysfunction, is approved and marketed in Japan for type 2 diabetes through a partnership with Sumitomo Pharma, generating royalties and milestone payments for Poxel SA. Key pipeline candidates include PXL065, a deuterium-stabilized R-pioglitazone that met its primary endpoint in a Phase 2 trial (DESTINY-1) for MASH, and PXL770, a direct AMPK activator advancing in Phase 2 for rare metabolic diseases. Founded in 2009 as a spin-off from Merck Serono's metabolic business, Poxel SA is headquartered in Lyon, France, with subsidiaries in Boston and Tokyo, and leverages expertise in cellular energy metabolism pathways. Operating in the biotechnology sector, it focuses on advancing programs through strategic collaborations while maximizing value from approved assets.